Evidence map›Paper›PMID 35001347›Full record

ArticleInternational journal of hematology2022

NK-cell post-transplant lymphoproliferative disease successfully treated by second allogenic hematopoietic stem cell transplantation in chronic active Epstein-Barr virus infection.

Sho Shibata, Yoko Takiuchi, Naoto Kawasaki, Yoshio Okamoto, Shojiro Inano, Akiko Fukunaga, Sumie Tabata, Ayako Arai, Ken-Ichi Imadome, Toshiyuki Kitano

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Sho ShibataDepartment of Hematology, Kitano hospital, Medical Research Institute, 2-4-20, Ougimachi, Kita-ku, Osaka, Japan.
Yoko TakiuchiDepartment of Hematology, Kitano hospital, Medical Research Institute, 2-4-20, Ougimachi, Kita-ku, Osaka, Japan. youtak@kuhp.kyoto-u.ac.jp.
Naoto KawasakiDepartment of Hematology, Kitano hospital, Medical Research Institute, 2-4-20, Ougimachi, Kita-ku, Osaka, Japan.
Yoshio OkamotoDepartment of Hematology, Kitano hospital, Medical Research Institute, 2-4-20, Ougimachi, Kita-ku, Osaka, Japan.
Shojiro InanoDepartment of Hematology, Kitano hospital, Medical Research Institute, 2-4-20, Ougimachi, Kita-ku, Osaka, Japan.
Akiko FukunagaDepartment of Hematology, Kitano hospital, Medical Research Institute, 2-4-20, Ougimachi, Kita-ku, Osaka, Japan.
Sumie TabataDepartment of Hematology, Kitano hospital, Medical Research Institute, 2-4-20, Ougimachi, Kita-ku, Osaka, Japan.
Ayako AraiDivision of Hematology and Oncology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.
Ken-Ichi ImadomeDepartment of Advanced Medicine for Virus Infections, National Center for Child Health and Development, Tokyo, Japan.
Toshiyuki KitanoDepartment of Hematology, Kitano hospital, Medical Research Institute, 2-4-20, Ougimachi, Kita-ku, Osaka, Japan.
Kitano Hospital · JPNational Center For Child Health and Development · JPTokyo Medical and Dental University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic active Epstein-Barr virus infection (CAEBV) is a systemic T- or NK-lymphoproliferative disorder (LPD) caused by EBV. Allogenic hematopoietic stem cell transplantation (HSCT) is the only curative therapy for CAEBV, but relapse sometimes occurs. Relapse is generally attributed to proliferation of recipient-derived CAEBV cells. We herein report a case of donor-derived CAEBV-like NK-cell post-transplant lymphoproliferative disease (PTLD) in a 41-year-old female after the first allogenic HSCT for CAEBV from an HLA-matched sibling donor. A second HSCT from an HLA-matched unrelated donor successfully controlled the disease, but EBV infection of cells derived from the second donor continued to be detected. Although the mechanisms underlying CAEBV and CAEBV-like NK-cell PTLD have not yet been elucidated in detail, the findings of the present case imply that host genetic factors, including familial factors, may be important in disease development.

Indexed as

Epstein-Barr Virus InfectionsHematopoietic Stem Cell TransplantationLymphoproliferative DisordersAdultFemaleHerpesvirus 4, HumanHumansKiller Cells, NaturalChronic active Epstein–Barr virus infectionHematopoietic stem cell transplantationPost-transplant lymphoproliferative disorder

Identifiers

PMID35001347
OpenAlexW4205870945

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.